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Summary: The aim of the Working Group was to describe guidelines for deriving desirable analytical goals in 
laboratory medicine. First, a literature review is given of the different approaches used until now, and some of the 
most important studies are presented in detail. These approaches are then discussed critically, and the analytical 
goals proposed by the group are outlined with respect to monitoring and diagnostic testing. The group recommends 
that, most realistically, analytical quality specifications be biologically based. For diagnostic testing, the aim is 
achievement of accuracy, allowing the use o f common reference intervals when populations are homogeneous for a 
given quantity. For monitoring (within an individual laboratory and performed with the same instalment), analytical 
performance should aim at stable operation and low imprecision compared with the within-subject biological varia­
tion. Method accuracy is also very important for the comparability of results from different laboratories or instru­
ments.
Foreword
The aim o f  the Working Group was to describe guide­
lines for deriving desirable analytical goals in laboratory 
medicine, Desirable means that analyses of the quality 
demanded by these goals have a negligible analytical
patient treatment strategies. In view of the complex and 
partly controversial nature o f this topic, the literature 
describing the different approaches used so far is re­
viewed, and some of the most important studies are dis­
cussed in detail [for recent reviews see also; Hyltoft Pet­
ersen & H0rder (1) and Fraser & Hyltoft Petersen (2)].
uncertainty (due to method bias, unspecificity, or im- shouM bg nQted that ¡n this review partj we cite the 
precision) for a quantity present in a specimen. The at- nomenclature used by the respective authors which, in 
tainment of such goals would increase measurement ^  leadg tQ inconsistencies in wording and terminol- 
comparability between different methods and laborato- Qgy During development o f  the Worldng Group’s con- 
ries, allowing the use o f common lefeience intervals and CCpt  ^we soon rCaIizcd that no universally applicable ap-
~  proach could be established. Every application requires
]) The Working Group is one of four ad hoc groups meeting under special consideration. Analytical quality specifications
the auspices of the European external quality assessment (EQA) for m0nitoring may be different from those for diagnos-
organizers group. The Working Groups were initiated by A. Uldall . • ^  _________ ______,
following a mooting of EQA organizers and interested individuals tic tcstinS- ^  situation in emergency analysis may dif- 
in Cracow, Poland, in 1991 at Eurolab ’91. fer from that in routine analysis (other techniques might
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be preferable in the former due to the necessity for a contributions to goal setting for quantitative meusuie-
short response time). Special population screening pro- ments in laboratory medicine leflect both analytical and
grammes may require detailed studies on the relation of medical points of view. Stiategies foi defining maxi-
cost to analytical performance. Specific clinical strate- mum analytical bias and imprecision include state of
gies require discussions with the clinicians involved, the art” of performance (7), opinions of experts (8 , 9),
Therefore, the Working Group restricted itself to out- national recommendations (10, 11), needs for quality
lining general analytical goals for monitoring and diag- control of analytical processes (12—16), proposals de-
nostic testing. These recommendations are presented in rived from the viewpoint of clinicians (17—22), analysis
detail here. The setting of analytical goals for clinical of the effect of performance on interpretation in specific
strategies is, however, not discussed [for more informa- clinical situations (1, 23—26), and derivation of criteria
tion see I.e. ( 1)1, based on intra- or inter-individual biological variation
(27-37).
Introduction
Analyses in laboratory medicine are only useful if mea­
surements of quantities allow the evaluation o f a per­
son’s state of health. This means that diagnosis or exclu­
sion of a disease, detection of a person’s predisposition 
to a disease, or monitoring during medical treatment is 
based on comparison o f a value with a set of appropriate 
population based reference intervals or with values pre­
viously observed from the same individual Two general 
aspects have to be considered when any kind of mea­
surement is performed: a) the “medical requirements” 
(clinical usefulness), i. e. what quality is needed for the 
measurement from the medical point o f view, and b) the 
“analytical performance”, i. e. how this desirable analyti- 
cal quality can be specified, achieved, and controlled. 
Factors connected with medical requirements are: with­
in- and between-subject biological variations of a quan­
tity, distribution of analytical results between sick and 
healthy subpopulations, prevalence of disease, use of an 
analysis (e.g. single point testing, patient follow up, 
population screening), and time of analysis. The distri­
bution of analytical results between sick and healthy 
subpopulations and the prevalence of a disease deter­
mine the “a priori” relevance of an analytical test used 
to decide whether a particular disease is present or not. 
A widely used approach to assess the relevance of a 
clinical test is the predictive value model which defines 
the diagnostic performance of a laboratory test by its 
diagnostic sensitivity, diagnostic specificity, predictive 
value, and efficiency. This model and other approaches 
are discussed in detail in recent articles by Linnet (3), 
Biittner (4), Christensen (5), and Henderson (6). Since
they are not directly related to analytical goal setting,
t
they will not be outlined here. Analytical performance 
is associated with: bias and imprecision of an analytical 
procedure, analytical specificity and detection limit, 
analysis costs, internal and external control, etc. Analyti­
cal performance and medical requirements both influ­
ence each other. Medical knowledge can guide analytical 
strategies, whereas analytical progress can promote bet­
ter understanding o f biological processes. Therefore,
Description of the Different Strategies
A naly tica l  p e r fo rm a n c e  and 
“ the s ta te  o f  the  a r t ”
According to some authors, the current state of the art 
achieved in laboratory medicine is already sufficient (7). 
Although this argument may be correct in many situa­
tions, it is untrue in many other situations, e. g. in certain 
fields of immunochemical determinations, in the case of 
recently developed analytical techniques without thor­
ough validation, or in cases where inherently superior
«
methods seem to disappear from the market because 
faster and cheaper assays become available. This means 
that the state of the art is not stable: it can change for 
the better but it can also deteriorate. Therefore, clear 
criteria should be defined concerning the analytical 
quality that is desired in laboratory medicine. Where this 
is impossible, at least criteria should be elaborated 
which can aid in the distinction between good and poor 
methods.
A n a ly t ic a l  g o a ls  a d v o c a te d  by e x p e r ts  or 
e x p e r t  g ro u p s
Analytical goals advocated by experts (8 , 9) are gen­
erally empirical in nature. They mostly reflect the ex­
perience gained in the special field in which the experts 
are involved. They often include compromises taking 
the state of the art very much into account and are not 
real goals for desirable analytical quality. The latter is 
especially true for the goals used by organizations re­
sponsible for external quality assessment or proficiency 
testing (10, 11, 38).
A n a ly t ic a l  g o a ls  and the  needs  o f  
q u a l i ty  c o n tro l
Discussion of analytical goals has become more and 
more influenced by the need for the quality control of 
analytical processes. Some general comments on quality
Eur J Clin Chem Clin Biochem 1995; 33 (No 3)
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control in laboratory medicine can be found in a series in the work of Skendzel et al. (20) were very useful,
of recommendations of the International Federation for provided that these values were interpreted so that they
Clinical Chemistry (IFCC) (39, 40), and in an article by reflect the sum of preanalytical (sp), within-subject bio-
de Verdi er et al. (41). The general statement from the logical (s*), and analytical standard deviation (sa): st =
viewpoint of quality control is that the better methods [Sp + s? -f Sa]1/2. If values for maximum analytical coef-
are, the less eifort and money has to be invested in their ficients of variation were then calculated from the medi-
control. On this basis, analytical imprecision expressed cally significant differences, they would be much lower
as standard deviation (su, see Annex for a list of abbrevi- than those proposed by Skendzel et al. (20). On the other
ations) of 1/4 of the total allowable error is recom- hand, it is possible that the medical decision limits them-
mendcd for internal quality control (14), which is half selves are based on the experience o f  the physicians with
that originally proposed by the same group (42). Results the performance of the analytical tests, and so more or
exceeding the total allowable error indicate that the ana- less reflect the analytical state o f the art. In other words,
lytical method is out o f control. Usually no estimates for it may not be possible to derive analytical goals from
the total allowable error (TAB) are derived in such medical decision limits because they themselves may be
works but the currently used strategies are assessed as strongly influenced by analytical performance, 
to whether they fulfil the needs for internal quality con­
trol (12, 13). In addition, no theoretical goals are derived 
for method imprecision, but the state o f the art is often
used as a basis for discussion, in order to estimate the 
sa/TAE relation necessary for appropriate internal qual­
ity control, The benefit of these studies is that they pro-
A n a ly t ic a l  g o a ls  d e r iv e d  f ro m  s p e c i f i c  
c l in ic a l  s i tu a t io n s
vide a variety of statistical methods for evaluating Every clinical situation requires a specific analytical ap- 
method performance in terms of bias and imprecision proach. Therefore, it is very difficult to establish a uni- 
(42-44), they discuss the quality control procedures form concept for the estimation o f allowable imprecision 
necessary for specific analytical performance (15, 16), and bias. Examples of specific situations are; determina- 
and they compare these strategies with those used in tion of haemoglobin A lc for long term diabetic control 
other scientific fields, e.g. industrial process manage- (25), determination of theophylline in serum for thera­
peutic drug monitoring (26), determination o f creatine 
kinase isoenzyme in the diagnosis o f acute myocardial 
infarction, determination o f  blood thyroid-stimulating
ment (14).
A n a ly tica l  g o a ls  d e r iv e d  f ro m  the  v ie w p o in t  
o f c l in ic ia n s
hormone in screening for congenital hypothyroidism, 
and monitoring cholesterol as a measure for the risk of
As discussed in the introduction, different types of medi- coronary heait disease (23). Furthei applications can be 
cal decisions may be based on the results of analyses found in a recent leview by Hyltoft Petersen Sc H0rder 
done in laboratory medicine. Therefore, the necessary a recent article, Schectman & Sasse (46) investi- 
quality of an analytical result depends both on the actual gated the influence of analytical impiecision on the 
clinical situation and on the physician who requested the medical usefulness of lipid measurements. The inter­
analysis. In some studies, attempts have therefore been pretation of the analytical performance was based on the 
made to derive analytical goals from the viewpoint of use of clinical cut-off points or comparison with desired 
clinicians by sending questionnaires to experienced concentrations. All of these approaches have in common 
physicians in many different fields of laboratory medi- ^iat theY evaluate the clinical consequences caused by 
cine (17—22). They were asked for decision levels for the analytical imprecision and bias either together or in­
common quantities in particular clinical situations or for dependently. Many different statistical approaches are 
changes which would cause their medical action (medi- used to calculate the effects at different levels o f corn­
eal significant differences =  Amed). In the work of plexity: e.g. sum of misclassifications, the number of 
Skendzel et ah (20 ), medically useful analytical coeffi- false negative results, or economical optimization. These 
cients of variation (CVa’s) were calculated in the approaches usually do not generate general figures for
analytical bias and imprecision, but they present models
When a patient’s value was compared with a reference for optimizing the analytical performance for the spe-
value, the calculation was as follows: CVU =  AmcU/1.65. cific clinical situations. Therefore, they are more or less
Compared with other proposals, these coefficients of restricted to specialists in the field. Nevertheless, the sta-
variation were often quite large and were the subject of tistical background outlined in these studies can also be
severe criticism (45). On the other hand, it was stated used for the optimization o f  analytical methods in other
(13) that the medically significant differences reported applications.
following way for monitoring; CVU =  AnìCa/[ 1.65x^2].
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A similar approach, which mainly discusses overlap of Following this hypothesis, data on biological variation 
healthy and sick subpopulations and prevalence of dis- were collected and goals for a variety of quantities were 
eases in the context o f  analytical needs is shown by Lott agreed on at two international conferences (30, 31). This
 ^ « f t  I
They data base was expanded and collected in a recent review
term
precision on the percentage of correct diagnoses at dif- (49), although data on individual within-subject biologi-
ferent levels o f prevalence and population overlap in cal variations have only be described tor a few quantities
three different applications, namely, population screen- (33, 50). It was further recommended (31) that the com-
and short term trend detection. posite biological variation be used for group screening,
and the within-subject biological variation for single in-
A general theory for the allowable analytical coefficient dividual testing, 
of variation in situations that specifically involve the
monitoring of individuals was proposed recently (24). The concepts outlined above mainly deal with method
The following formula was derived: CVa <  [(A2/2Z2) imprecision, but it has become increasingly apparent
-  CV?]1/2, where Ac is the percentage of change with that method bias (expressed as the deviation from the
clinical significance in monitoring serial results from an “true value”) should be included when analytical goals
individual, Z is a statistical value for the probability of in laboratory medicine are derived, Therfore, Harris (51)
significance, and CVj is the within-subject biological co- expanded his original work (32) so that bias (B) and
efficient o f variation. A critical point o f this approach is imprecision were both taken into account. The original
the estimation of the Ac value. In the work mentioned equation: sa ^  0.5 s{ (sc) was thus changcd into
above, Ac was often derived from the viewpoint o f clini- [s2 +  B2] 1/2 ^  0.5 Sj (sc). In addition, the author focused
cians (questionnaires), which perhaps does not reflect in this work on diagnostic testing, especially when com-
the desirable analytical quality but might be much influ- paring patients5 data with a reference interval of the
enced by the analytical state o f the art as mentioned healthy subpopulation, an idea originally proposed by 
above. Tonks (27) and later by Glide (29) [a series of rceom-
A n a ly t ic a l  g o a ls  b a s e d  on  w i th in -  and  
b e tw e e n - s u b je c t  b io lo g ic a l  v a r ia t io n
mendations on the theory of reference values was re­
cently published by the IFCC, see 1. c. (52) and articles 
cited therein]. As stated before, the reference interval 
reflects the within- and between-subject biological vari­
ation and, if  the 95% interval is chosen, then R =  4 sc.
The approach of relating analytical performance to the The formula for the allowable standard deviation (taking
biological variation was very much inspired by the ideas into account method bias) of an analytical method for
of Tonks (27). He empirically stated that the total allow- single diagnostic testing becomes: sa < R [ l /8 0  - 4 / 5
able error (TAE) should not exceed one quarter of the X B2/R2] 1/2, or B <  0.125 R, if sa is zero. As a rule of
reference interval (R), using the following formula: TAE thumb, he still proposed sa ^  0.5 s* for single serial test-
l/4[of the reference interval]/[mean of the reference ing, and sa < 0 .1  R for single diagnostic testing in the
interval] X 100%. absence of method bias.
Codove et al. (28) proposed that analytical goals be Ross (53) uses the preanalytical test diagnostic effi- 
based not on the reference interval, because this reflects ciency as a starting point. Fie considers in particular the 
both the analytical and the biological variation (48), but case in which the best performance is needed. This is 
on the composite biological standard deviation (sc), the case when the means of the healthy and sick subpo- 
which includes the within- (Sj) and the between-subject pulations are only 1.88 SD’s apart. The preanalytical
diagnostic efficiency is then 82.5%, which means that 
2.5% true diagnostic statements can be made in the
or group standard deviation (sg). They stated that the 
analytical standard deviation should not exceed 0.5 
times the composite biological standard deviation: ideal case. In that situation, he examines the loss of 
0.5 sc, with sc =  [s2 +  s2] 172, because then the ana- diagnostic efficiency depending on the bias or the im­
precision of the analytical method used, the test popula­
tion variability and the probability for false rejection.
s
lytical imprecision adds only 12% to the total test result 
variability: st =  [(0,5 sc)2 + s2] 1/2 = 1 .1 2  sc. In fact, this
formulation is similar to the one originally proposed by The output of the model is the limit for allowable analyt- 
Tonks (27) because the total allowable error defined by ical error of a single result for a quantity in the clinical 
him was meant as 2 sa. In addition, 95% of the reference population under study. The advantage of this model is
interval represents the mean ±  2 s 4 sc, if corrected 
formula can then
be written as: 2 s 
as the formula de
that it not only relates method bias and imprecision to 
the biological variance, but it additionally shows how 
0.25 X 4 X sc, which is the same both variables affect the confidence level of medical de~
d by Cotlove et al. cisions. The disadvantage is its limitation to the situation
Eur J Clin Chem Clin Biochcm 1995; 33 (No 3)
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of a bimodal distribution with a 50% prevalence where M odern Concepts for Assessing M ethod  Bias 
the means are 1.88 SD’s apart from each other. For indi­
vidual single testing he proposes sa <  0.64 Sj. In a recent As.shown above’ on,y the newer concePts relating ana'
article (54), this concept was expanded and sa <  0.5 Si 
and B ^  0.25 to 0.33 Si were advocated. Further, total 
allowable analytical error should not exceed 1.25 to 
1.40 times s*.
performance
ence o f  bias on the medical usefulness o f  the analytical 
result. The reason for the late introduction o f  the bias 
component in the discussions on desirable performance 
standards in laboratory medicine is that for a long time
Gowans et al. (35) based goals on the recommendations otlly a limited accuracy base existed. This changed,
of the IFCC regarding reference intervals (52). They de- when so calIed “Definitive Methods” were developed,
rived functions which allow the investigation of the in- which are the “best approximation to the true value” 
fluence of analytical bias and analytical imprecision of a clualit>'- Based on this approach, a comprehensive
(separately and in combination) on the percentage of the measurement system in laboratory medicine was pro­
population outside reference limits. For a population Posed by Tietz (57). An important role in this concept is 
sample size o f 120, the IFCC stated that the maximum pIayed by the “Reference Methods”, which are intended 
acceptable percentage outside each reference limit ^  transfer the accuracy base o f  the Definitive Methods
should be 4.6%. From this, a maximum analytical stan- to t'ie rout n^e methods (58—60). The bias o f methods is 
dard deviation (with no bias) o f s, < 0 .5 8  sc, and a max- of Particular importance when intermethod or interlabo-
imum bias (with no imprecision) o f B <  0.25 sc is calcu- ratory comparability is required. Both features are pri-
marily assessed in external quality assessment (EQA)
surveys and therefore the approach of Tietz was recom-
A similar approach was proposed by Stamm (55). For mended early in this field (9, 61—63). Comparison of
diagnostic testing he proposed a maximum method bias routine methods in laboratory medicine with accuracy
based methods have been published (64—66) and mean­
while some countries use an accuracy base for perfor-
lated.
of 0.33 sg together with a maximum standard deviation 
of 0.33 Sy, in order to keep the sum of false classifica­
tions below 5% on each side o f the reference interval. mance evaluation for a variety o f  quantities in their in-
For monitoring, on the other hand, only limits for teraaI and external quality assessment programmes (10,
method imprecision were proposed. Further, these limits ^7, 68). 
were not directly related to the biological variation, but 
were expressed as 1/4 of a predefined medical decision
limit.
Klee (56) investigated the influence o f imprecision and 
bias of a test on its clinical specificity. He defined an 
analytical “error budget” as the squared sums of the im­
precision and bias errors. The maximum limit for this 
error budget was set at a value corresponding to a 50% 
increase in the false-positive rate for classifying healthy 
subjects. For Gaussian distributions with ±  2 s used as 
decision limits, this budget equates to 0.45 sc. He recom­
mended that this budget be allocated as 0.36 sc for bias, 
and 0.18 sc for the analytical standard deviation (these 
fractions do not add up to 0.45 because bias and im­
precision are not additive; the bias has a greater influ­
ence on false classification than imprecision).
A striking feature is the fact that all o f the individual 
approaches described above recommend numbers for 
analytical standard deviation near or equal to 0.5 times 
the biological standard deviation. In addition, the later 
studies split this number into portions for imprecision 
and bias, if both are present (35, 51, 55, 56); only 
Ross & Fraser (54) use the sum of the numbers 
derived for maximum bias and imprecision, if both 
are present.
Comparison of the Different A pproaches
In table 1, some examples o f the maximum medically 
useful analytical coefficients o f variation proposed in the 
literature for single individual testing are compared with
Tab. 1 Maximum medically useful analytical coefficients o f vari­
ation proposed in the literature for single individual testing and 
analytical “state of the art”.
Quantity Proposed analytical coefficient of variation 
from references*
(69) (30) (10) (9) (20)H (27)
S-Sodium 0.9 0.3 2.0 1.1 1.7 0.9
S-Chloride 1.2 0.7 2.0 1.5 1.0
S-Calcium 1.5 0.9 3.3 1.5 4.8 —
S-Protein 1.5 1.4 3.0 3.3 8.3 3.5
S-Glucose 2.1 2.2 5.0 3.0 11.2 5.0
S~Creatinine 2.0 2.2 6.0 6.7 10.1 —
S-Potassium 1.4 2.4 2.7 5.0 4.8 —
S-Cholesterol 2.6 2.7 6.0 6.0 12.3 5.0
S-Phosphate 2.2 4.0 5.0 5.0 14.3 5,0
S-Uric acid 2.2 4.2 6.0 6.3 — —
S-Urea 2.5 6.3 8.0 10.0 12.2 5.0
* Median CVa obtained from the Netherlands external/internal 
quality assessment scheme (69); Aspen conference (30); German 
Guidelines (10); Gilbert (9); Skendzel et al. (20), “whenever two 
values are given, the lower is listed; Tonics (27).
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the state of the art as derived from external quality as- laboratories will accept them. Disadvantages aie that
sessment data (69). The concepts related to these exam- they might not be related to optimal patient care and that
pies were discussed earlier in the review part. In all these analytical quality specifications change with time,
cases the between day analytical coefficient of variation The state of the art can improve, but it can also deterio-
is considered. The data in columns 4 +  5 refer to medi- rate, 
cal decision limits as specified in the respective publica­
tions, while the data in columns 1 - 3  were given by the
respective authors without restriction to specific concen- The v *ews o f e x p e i t s  and e x p e i t  g io u p s
trations. In this way, the decision levels are included in Advantages are that they can be easily established on a
the latter, which allows the comparison of both types of local basis and will gain a high acceptance in laborato-
data. The data o f Tonks (27) in column 6 are shown only ries> Disadvantages are that these analytical quality
for historical reasons. With the exception of S-urea, the specifications often cannot be transferred to a broader
goals derived from the within-subject biological varia- community an(j that they often are influenced by the
tion are the most stringent (column 2). The most liberal analytical state of the art. 
goals are those obtained from physicians’ interviews 
(column 5), Between them lie the goals advocated by
experts and national recommendations (columns 3 +  4). ( iii)  O p in io n s  o f  c l in ic ia n s
Interestingly, most o f these follow in general the de­
mands given by the biological variation of the quantities, 
e, g. for S-sodium the proposed CV are always the low-
The advantages of this concept are that it may be related 
to the clinicians'5 perception when to react. In addition,
est ones. For S-uric acid or S-urea usually quite high CV the analytical quality specifications derived represent
are tolerated. But there are examples where quantities more or less the situation used in practice. Disadvan-
with comparable biological variations show pronounced taScs are that often different °Pinions am on8 clinicians
differences, e. g. S-creatinine and S-potassium, The vai exist and that it is often impossible to fix the probability
ues for S-potassium are considerably lower (see columns e^ve  ^ 0^l siSn^ lcance of lcsults. In addition, the analyti- 
3 -5 ) .  This could be due to the fact that many methods cal specifications derived might be very much
for S-creatinine today still have accuracy and precision influenced by the analytical state of the art. The latter
problems, while S-potassium normally is measured with will be discussed in more detail below. Some studies
methods o f higher precision. It seems that the goals for ma^e an attempt to derive analytical quality specifica-
S-creatinine and S-potassium derived by experts, exter- *|ons l^om *he viewpoint of clinicians by sending ques-
nal quality assessment organizers or questionnaires of tionnaiies to experienced physicians in many dilieient
clinicians reflect more or less the analytical state of the fislds of laboiatory medicine (17—22). They were asked
art for these two analytes. The comparison of the state 0^1 decision levels for common quantities in particular
of the art CV (69) (column 1) with the most stringent climcal situations oi foi changes in concentrations
goals proposed at the Aspen Conference (30) (column 2) which would cause theii medical action. It was shown
shows that the analytical precision is now satisfactoiy decision limits given in the woi'k ol Skendzel et
for most o f the presented quantities, provided the meth- aL ^  wiU cause <  5% false Positive alarms for most
ods have no bias. Exceptions are analytes such as S- of the common quantities, when the observed analytical
sodium, S-chloride and S-calcium, for which the biolog- resuIts exceed these action limits’ Pro v ided the results
ical variation is very small. An interesting feature in the were obtained with state of the art analytical pcrfor-
numbers advocated by Tonks (27) (column 6) is the ten- mance ( I3)‘ This suPPorts the conclusion that these ac-
dency to set an upper imprecision limit, even if biology tion limits mi§ht be influenced to a great extent by the
would allow higher values. This might reflect the fact analYtical state of the art. But is was also stated that the
that different quantities are often measured with similar medical significant differences may be too narrow for
methods and equipment, which results in similar im- some quantities, because the clinicians seem to underes­
timate the biological variation of those quantities (13).precision.
In addition, it can be questioned, whether others are not 
unnecessarily high. To investigate this problem in more 
Comments of the Working Group on the Approaches detail, the within-subject biological variation (CV;), the
in the Literature for Deriving Analytical Quality 
Specification from:
(i) T he  s ta te  o f  th e  a r t
Advantages of this concept are that analytical quality 
specifications can easily be established and most
analytical variation (CVa), and the medical decision val­
ues must be viewed in relation to each other. Table 2 
compares the quotients of CV0 and C V i% Amctl and CVj 
and CVj for some of the common quantities [they are 
arranged by descending CVJCV\ values, and the data 
of Linnet (13) are used]. From these calculations it is
Eur J Clin Chem Clin Biochem 1995; 33 (No 3)
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Tab. 2 Comparison of CV„/CVj, Amcd/CVj, and CVi of 17 com­
mon quantities arranged by descending CV^/CVj values [the data 
of I.e. (13) are used for the calculation].
Quantity
n 
o
 
<
,< A,ned/
CVi
CVj
S-Sodium 1.49 4.5 0.8
S-Creatinine 1.39 5.89 4.4
S-Calcium 1.33 5.39 1.8
S-Thyroxine 1.18 5.0 7.6
Prothrombin time Ü.85 5.58 4.5
S-Glucose 0.79 5.09 4.4
S-Cholestero! 0.79 4.23 4.8
S-Total protein 0.74 4.57 3.0
S-Phosphate 0.60 4.43 5.8
S-Potassium 0.48 2.70 4.4
S-Bilirubin 0.48 1.87 23
S-Aspartate aminotransferase 0.43 2.39 14
S-Urea 0.37 2.48 12.4
Haemoglobin 0.24 1.69 4.5
S-Triacylglyccrols 0.21 1.02 26
Leukocyte count 0.17 1.71 14.7
S-Iron 0.12 1.09 26
(v) A n a ly t ic a l  g o a ls  d e r i v e d  f ro m  s p e c i f i c  
c l in ic a l  s i tu a t io n s
Advantages of this approach are that generally analytical 
imprecision and bias are evaluated. In addition, the goals 
derived are directly related to the clinical use. They are 
most useful when one particular test is used for one spe­
cific clinical situation. Disadvantages are that they are 
complicated, often require much effort for their pro­
duction, mostly can be used only on a local basis, and 
that the clinical strategy must be clearly defined. In ad­
dition, this approach lacks practicability for laboratory 
tests that are used for many different clinical situations. 
Nevertheless, the group advocates this approach wher­
ever it can be applied. A detailed description o f  its appli­
cation in various clinical strategies can be found in Hyl- 
toft Petersen & H0rder (1).
(v i) A n a ly t i c a l  g o a ls  b a s e d  o n  w i th in -  an d  
b e tw e e n - s u b ju c t  b io lo g ic a l  v a r i a t i o n
The basis of this concept is that the mean within-subject
surprising that the quantities with a low (<  0.5) CVa/ biological variation is nearly constant in all investiga-
CVi value (which indicates sufficient analytical tions (49) including the elderly (70) and groups o f pa-
precision) also have a low Amcj/CVi value (the “a priori” tienis in certain stable states (49). This allows the
least medical significant difference which analytically transfer o f data over time and geography. Further, where
can be detected for two consecutive measurements ^le population is homogeneous for a quantity, common
(P = 0.05) is: Amcd =  2.77 X CVi, which would result reference intervals can be used within large regions or
in an ideal A mJ C V { value of 2 .77 ). It seems that the within ethnic SrouPs* This can save considerable re­
medical decision limits have been chosen to be quite sources in laboratories which otherwise have to establish 
narrow despite the fact that these quantities mostly have ^ e ir  own reference intervals. In addition, the concept of 
a great biological variation. In other words, this varia- common reference changes (33) could be applied in 
tion seems to be underestimated by clinicians with the the whole of Europe (and even more widely). Foi a more 
consequence that the number o f false positive results is recent article on the concept o f reference changes see 
high (13). On the other hand, many quantities with a Queralto et al. (50).
high (> 0 .5 )  CVu/CVj value (which indicates insuffi­
cient analytical precision) have high Amcj/CV| values.
In these cases, it can be questioned whether the medical The Concept of the W orking G roup
decision limits should not be lowered. Maybe the poor C la r i f ic a t io n  o f  the  te rm s  “ g o a l ” a n d
analytical imprecision has been overestimated here by “ d e s ira b le  a n a ly t i c a l  p e r f o r m a n c e  s t a n d a r d ” 
the clinicians, A result of this is a relatively high
number of false negative results. Therefore, analytical Sometimes confusion arises over the use of the word
goal setting on the basis of the viewpoint of clinicians “goal” for both medical and analytical aims; in fact they
seems to be more influenced by “the state of the art” should be clearly separated. A medical goal is, e, g. the
than by what is desirable. In addition, it may lead to llse common refeience intervals. For this medical
incongruent decision limits when different quantities goal# a desirable analytical peiformance standaid 
are compared “analytical goal”) must be derived. This desirable an­
alytical performance standard must then be specified in 
terms of maximum method bias and imprecision. When 
achieved, these performance standards should guarantee 
optimal patient care. To illustrate this way o f  thinking, 
Scheme 1 presents some analytical goals for different 
As stated above, this approach usually uses only cur- application levels (we use the term “analytical goal” in 
rently defined goals and investigates whether they are in the following always in the sense o f  “desirable perfor- 
accordance with the needs for quality control.
(iv) A n a ly t ic a l  g o a ls  and  the  n e e d s  o f  q u a li ty
con tro l
mance standards”, as described above). Two main levels
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Scheme 1 Goals and related desirable analytical performance standards at different levels
Level
Achieving 
medical utility
Accreditation
Goal
1. Make use of:
a. Common reference changes
b. Common reference intervals
2 . Analytical performance should not 
influence the outcome of clinical 
strategies
Guard against unprofessional 
performance
Desirable performance standards
In the absence of systematic changes: sa ^  0.5 S| 
(see Annex for detailed discussion)
When imprecision is negligible: B 
(see Annex for detailed discussion)
0.25 s,
The demands implied for desirable performance should be evaluated 
for each clinical strategy according to accepted models for the 
specific purpose (diagnosis, screening, monitoring, etc.)
The specifications must consider the analytical state of the art, but 
should gradually be converted in accordance with the above 
recommendations.
are shown in Scheme 1, which indicate differences in 
approach. Achieving medical utility is always related to 
biology whereas accreditation systems are mostly re­
lated to the actual analytical performance attained in 
laboratories. The latter uses goals from biological varia­
tion only if  convenient This is practical, since it reflects 
what is possible with the methods and equipment in use, 
but it may not reflect the medical utility. It is obvious 
that also the EQA of accreditation/licensing testing has 
to consider the state o f the art performance, but a grad­
ual conversion of systems should be undertaken in ac­
cordance with medical utility concepts whenever pos­
sible.
R e c o m m e n d a t io n s  o f  th e  W o rk in g  G roup
From the above discussions, the Working Group recom­
mends that analytical quality specifications be based on 
biology as a realistic basis, and that the approaches (i) 
to (iii) are reasonable only for providing provisional so­
lutions: the first in assessing surveys and the other two 
as interesting approaches in individual laboratories. The 
starting point for our work was, therefore, the concept 
of Harris (32) and Cot love et al. (28) for patient moni­
toring: sa ^  0.5 si} and the approach of Gowans et al. 
(35) for diagnostic testing: B <  0.25 sc. We expanded 
the concept of Cotlove et al. (28) because, during moni­
toring, unidirectional systematic changes (ASE) (=  
drifts) can occur, and we accepted the concept o f Gow­
ans et al. (35), who based their goals on the recommen­
dations of the IFCC for the establishment of reference 
intervals (52). This concept is especially useful for diag­
nostic testing. A detailed discussion of the derivation 
of analytical quality specifications for monitoring and 
diagnostic testing can be found in the Annex. In particu­
lar, the combined effect of bias and imprecision is pre­
sented in a graphical form. In short, we recommend that 
desirable performance standards should be calculated
for monitoring as:
Sa ^  0.5 Si
(in the absence of unidirectional systematic 
changes), or
ASE :£ 0.33 Sj (when imprecision is negligible); 
see also Annex;
for diagnostic testing as:
B <  0.25 sc (when the imprecision is negligible), 
or
sa ^  0.58 sc (when bias is negligible); 
see also Annex.
Data on biological variation for most of the common 
serum quantities are available (49, 71—73) and the de­
sired performance standards can be calculated as shown 
in table 3 (74). If data for sg are not available, an approx­
imation for bias can be 1/16 of the range of the reference
Tab. 3 Specifications for desirable analytical performance (from 
I.e. (74))
Quantity Maximum CVn in 
the absence of 
syst, changes 
(using CVa 
<  0,5 CVj)
Maximum bias
(%) if the
imprecision 
is negligible 
(using B 
<  0,25 CVc)
S-Sodium 0.3 0.2
S-Calcium 0.9 0.7
S-Creatinine 2.2 2.8
S-IgM 2.3 12.7
S-Potassium 2.4 1.6
S-Transferrin 2.4 2.3
S-Cholesterol 2.7 4.1
S-Lactate 3.9 4.1
S-Phosphate 4.0 3.1
S-Bilirubin 11.3 9.8
S-Triacylglycerols 11.6 15.6
S-Alanine 13.6 13.6
aminotransferase
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interval (this assumes that sa is small in relation to sj 
and sg). We recommend that these desirable performance 
standards should also be introduced in external quality 
assessment as the basis for calculation of acceptance 
limits. When more demanding specifications based on 
documented medical needs are stated, these may be sub­
stituted for those based on biological variation. The 
goals outlined above may be viewed as aims for the 
future if they cannot be reached with current analytical 
equipment and methodology. Last, but not least, the 
group recommends that limits for interference and un­
specificity should be related to the biological variation 
of the respective quantity (75). This is more relevant 
than the fixed limits used previously [e.g. 5% for 
electrolytes and substrates and 10% for enzymes (76); 
or 3% (77), and 10% (78) for all quantities]. Further, the 
group recommends the use of goals derived from spe­
cific clinical situations (1, 79) whenever they are more 
appropriate.
Comparison of the Recommendations 
with the Actual Situation
It should be noted that, for a number of quantities, the 
“state o f the art” analytical precision is better than the 
goals. Consider for example S-triacylglyceroIs. The pro­
posed maximum coefficient of variation was 11.6% (see 
tab. 3). If unidirectional systematic changes are also 
taken into account, it must be reduced to maybe 6 or 
8%. Much lower values are attainable today. Therefore, 
in the opinion o f the Working Group, it would neither 
be wise nor reasonable if a new triacylglycerol method 
with a CV in the range of 6% was introduced on the 
market, First, it must not be forgotten that an analytical 
standard deviation of 0.5 s,-, still adds 12% variation to 
the true test variation. In addition, it generally can be 
stated that the better a method performs, the less time 
and money has to be invested in its control (14). There­
fore, in the above cited example, more stringent criteria 
than those derived from the biological variation are ad­
visable. On the other hand, there are many quantities 
whose analytical precision is insufficient according to 
the above cited concept, especially when method bias is 
taken into account. Insufficient analytical precision is 
normally associated with quantities which have narrow 
biological variation like S-sodium, S-chloride, S- 
calcium or S-protein, despite the attainment of quite low 
CV values for these quantities. Therefore, in these 
cases, performing more than one measurement might 
be more effective than aiming for a CV below 0.5%. 
Then less stringent criteria than those derived above 
could be accepted. Even more difficult to achieve is a 
method bias below 0 .5%, because then the temperature 
during analysis must be kept constant or be constantly
monitored, because densities o f  solutions, and there­
fore their concentrations, change with temperature. 
This has an effect of about 0.12% within a temperature 
change of 5 degrees. In addition buoyancy corrections 
should be made for weighings, and so on (80). An­
other consequence would be the necessity to keep 
preanalytical errors below 0.5%, otherwise the final 
result would be dominated by the preanalytical errors. 
Taking all these sources o f error together, routine 
method inaccuracies below 1% are extremely difficult 
to achieve, it may even not be possible to assess them 
and they might be outweighed by the preanalytical 
errors. Therefore, accuracy seems to be a major chal­
lenge for future developments.
Conclusion
The proposed “desirable performance standards” are 
based on within- and between-subject biological varia­
tion for several reasons, namely
a) the model is simple to understand and apply,
b) there are many data on biological variation,
c) the within- and between-subject biological variations 
are nearly constant over geography, and
d) when these criteria are fulfilled, the analytical quality 
will satisfy most clinical needs.
Furthermore, it is often difficult to evaluate clinical 
needs in complicated clinical situations in which other 
considerations may be more relevant in the process of 
decision-making. However, when more demanding clin­
ically derived specifications are stated, these might be 
substituted for those based on biological variation. This 
may be the case for S-cholesterol (tab. 3) for which the 
National Cholesterol Education Program (11) recom­
mended a bias o f  less than 3%. Further, we recommend 
that where the state of the art is much better than the 
desirable performance standards derived from the bio­
logical variation, this should be welcomed because it 
gives the user additional benefits, especially in the in­
ternal quality control of such methods.
ANNEX
Detailed Concept of the W orking Group for Deriving 
Analytical Quality Specifications from Biology
Abbreviations used:
Within-subject (individual) biological standard 
deviation:
Eur J Clin Chem Clin Bioehem 1995; 33 (No 3)
166 Stòckl et al.: Desirable routine analytical goals
Between-subject (group) biological standard deviation:
sg
Composite biological standard deviation:
Sc =  (S? +  S |)1/2
Analytical imprecision expressed as standard deviation:
'a
Coefficient of variation:
CV (the same subscripts as above are used, e. g. CVO
Bias: B
Drift (unidirectional changes in bias):
A SE
change”) concept (33). This concept considers the case 
of two consecutive measurements (xi and x2) performed 
under identical analytical conditions, with the assump­
tion of normal distributed x values. In addition both 
measurements are performed on the same underlying 
population (jii =  n2)* Then, the smallest medically sig­
nificant difference (Amed) which analytically can be de­
tected for two consecutive measurements (P = 0.05)
(sa 0) is: 
Amed 1.96 x yjl x Sj =  2.77 x (i).
Two important cases have to be considered for monitor- 
Shift (difference in bias when two methods are used for ing: a) A SE >  0; b) sa >  0. Therefore, equation (i) has 
monitoring the same patient, see Lc. (81)): to be rewritten as follows (25):
A SE
Reference interval (for normal distributed quantity): 
R  (=  jut ±  1.96 s)
Medically significant difference (reference change):
A
Alnif»mcd 2.77 x (sa + s?)I/2 +  A SE (ii).
med
If A SE =  0 , Araed is only dependent on sa and sj, and 
we can use the concept o f Harris sa ^  0.5 Sj (32). From 
this follows:
<  2.77 (0,25 s? + s?)1/2Amed
Ajncd ~  3.10 Sj (Üi).G e n e ra l  a s s u m p t io n s  u n d e r ly in g  the  c o n c e p ts
We wanted to develop a concept to be generally applica- Now the case sn — 0 shall be consideied. We stait again 
ble in the routine laboratory. Consider, for example, the equation (ii); with sa — 0, and Amcti ^  3.10 Sj as
case of a potassium test to be used in a general medical calculated in (iii):
laboratory. The test should cover potassium determina­
tion in plasma in emergency situations, such as digitalis 
poisoning, heart arrhythmias, acute renal failure, or diar-
2.77 x Si + A SE ^  3.10 % giving 
A SE <  0.33 Si (iv).
rhoea; in therapy decisions, such as treatment with an- At this stage, we have derived maximum values for sa 
giotensin-converting enzyme blocker, digitalis, or di- (with A SE =  0) and A SE (with sa =  0). Now the func- 
uretics; or in monitoring illness, such as diabetes melli- ti°n describing the combined effect of both is presented, 
tus, chronic renal failure, or gastrointestinal diseases. The combined effects of drift and analytical imprecision, 
These are situations, which today, can normally all be related to biology, can be represented by figure 1 (25). 
covered by one and the same test. Developing general ^  covers the case for which, due to analytical uncer- 
goals for such a test means that the proposed goals tainty, the ideal medically significant difference of 
should be independent of the concentration of potas- 2-77 Sj has to be widened to 3.10 sj. It should be noted 
sium present in a specimen. It also follows that we 
always considered a Gaussian distribution and 5% test- 
level. Therefore, these goals are not ideal because they 
are not the best choice for each particular application.
But, on the other hand, it is our conviction that they 
are especially useful for the daily routine operation of 
a typical medical laboratory. We advocate to use % 
bias and CV to express the maximum analytical bias 
and imprecision derived by the concept below, because 
laboratories are more familiar with this way of pre­
sentation than with absolute numbers o f bias or stan­
dard deviations (for examples see tab. 3).
A n a ly t ic a l  q u a l i ty  s p e c i f i c a t io n s  fo r 
m o n i to r in g
The analytical specifications shall be derived from the 
least “medically significant difference” (“reference
Fig. 1 Reference change (AmctJ) concept: relationship between 
maximum allowable drift and analytical standard deviation in frac­
tion of (A SE/sj) and (sa/sj), respectively. The figure represents 
the case Ametl = 3.10 sj [from L c. (25), with permission].
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that any combination o f bias and standard deviation be­
low this curve would allow reduction of Amed to values 
between 2.77 and 3.10 Sj. Further, the values of the func­
tion for A SE =  0 and sa =  0 are the same as calcu­
lated above.
A n a ly t ic a l  q u a l i ty  s p e c i f i c a t io n s  fo r 
d ia g n o s t ic  te s t in g
The analytical specifications are outlined for sharing 
common reference intervals, according to the concept of 
Gowans et al. (35). This concept investigates the influ­
ence of method bias and imprecision on the percentage 
of individuals outside each reference limit for a normal 
distributed reference population. In figure 2 (35), the 
combined effects of bias and imprecision place 4 .6% of 
a population outside of each reference limit (with zero 
imprecision and bias, this is 2.5%). Again, the two ex­
treme cases, bias =  0 or sn =  0 can be read from fig-
ure 2 :
sa ^  0.58 sc (v), for bias =  0 
B :< 0.25 sc (vi), for imprecision =  0.
W sc
Fig. 2 Common reference interval concept: relationship between 
maximum allowable bias and analytical standard deviation in frac­
tion of sc, (|B|/sc) and (sa/sc), respectively. The figure represents 
the case that 4.6% of the individuals are outside each reference 
limit due to analytical uncertainty [from 1. c. (35), with permission].
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